Search Results for keywords:"synthetic opioids"

The President issued Executive Order 14228, amending a previous order (Executive Order 14195) to increase tariffs on products from China from 10% to 20%. This decision was made because the Chinese government has not taken adequate steps to address the inflow of synthetic opioids, like fentanyl, which poses a threat to U.S. national security and economy. The order underscores that it is consistent with applicable law and does not confer any new rights enforceable at law.

The document is a proposed rule by the U.S. Customs and Border Protection (CBP), under the Department of Homeland Security and the Department of the Treasury, which seeks to amend the regulations for low-value shipments valued at $800 or less. CBP aims to create a new process for these shipments to better target high-risk consignments, including those possibly containing illicit substances like fentanyl. This new "enhanced entry process" involves electronic data submission for a more efficient screening and clearance, while also offering a modified version of the current "release from manifest" process, now called the "basic entry process." Comments on the proposed changes are invited from the public until March 17, 2025.

The Executive Order 14195, issued by President Donald J. Trump, addresses the impact of synthetic opioids, mainly from China, on the United States. It highlights that these opioids cause significant harm, including deaths and societal issues, and criticizes China's role in the drug trade. To counter this, the order expands a national emergency declaration, mandating an additional 10% import duty on Chinese goods, subject to certain conditions. This action aims to pressure China into taking more stringent measures against illegal opioid distribution.